A phase 1/2 dose-finding, safety, and activity study of cabazitaxel in pediatric patients with refractory solid tumors including tumors of the central nervous system.

Authors

Peter E Manley
Tanya Trippett
Amy A Smith
Margaret E Macy
Sarah E S Leary
Jessica Boklan
Kenneth J Cohen
Stewart Goldman
Lindsay B Kilburn, George Washington University
Girish Dhall
Jeanne Devin
Cynthia E Herzog
Sonia Partap
Floris Fauchet
Emmy Badreddine
John P Bernard
Susan N Chi

Document Type

Journal Article

Publication Date

9-1-2018

Journal

Pediatric blood & cancer

Volume

65

Issue

9

DOI

10.1002/pbc.27217

Keywords

Adolescent; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Child; Child, Preschool; Drug Hypersensitivity; Female; Gastrointestinal Diseases; Glioma; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Metabolic Clearance Rate; Neoplasm Recurrence, Local; Neoplasms; Progression-Free Survival; Taxoids; Treatment Failure

APA Citation

Manley, P., Trippett, T., Smith, A., Macy, M., Leary, S., Boklan, J., Cohen, K., Goldman, S., Kilburn, L., Dhall, G., Devin, J., Herzog, C., Partap, S., Fauchet, F., Badreddine, E., Bernard, J., & Chi, S. (2018). A phase 1/2 dose-finding, safety, and activity study of cabazitaxel in pediatric patients with refractory solid tumors including tumors of the central nervous system.. Pediatric blood & cancer, 65 (9). http://dx.doi.org/10.1002/pbc.27217

Peer Reviewed

1